GIST Support International - logo

GIST Support International - Drugs to Watch
GIST Imagery

Drugs to Watch

These drugs are ones to keep an eye on when they get to trials.

New KIT inhibitors

Deciphera Pharmaceuticals is developing a new oral KIT inhibitors (DCC-2618) that is active against mutations associated with imatinib resistance because it uses a novel "switch pocket" binding strategy instead of competing with ATP for the normal binding pocket.  It is expected to enter a Phase I trial in late 2011.

Link here to the company's webpage.   A paper about these new KIT inhibitors was presented in April 2009 at the AACR meeting.  Deciphera has aleady begun a trial of a leukemia drug with a similar method of action (therefore immune to secondary mutations). 



Investigational Drugs Against the Insulin-like Growth Factor Family

For summaries about the insulin-like growth factor (IGF) signaling family, please link to these pages on our site:

Several drugs aimed at inhibiting IGF family targets are in clinical trials at present, with some trials for which GIST patients are eligible.  Please see our page Insulin-like Growth Factor Pathway Inhibitors for those options.

Below are drugs to consider when they do appear in trials that accept GIST patients.

AMG 479

manufacturer website link Amgen, Incorporated 

oral or intravenous: Intravenous

Description from AMGEN site: AMG 479 is a fully human monoclonal antibody that binds to insulin-like growth factor-1 receptor without cross-reacting with the closely related insulin receptor.

Ongoing Trials:
This drug is in several trials, but none so far are applicable to GIST patients.
For a search on click here:


manufacturer website link:  Novartis 

oral or intravenous: Oral

Ongoing trials:  none yet, but one may be planned at Fox Chase based on the tesults on GIST cells at Andrew Godwin's lab (see link at top of section).

Abstracts in PubMed: click here for search results


manufacturer website link

oral or intravenous: Oral

Description from NCI Drug Dictionary: An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGFR-1 stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.

Trials (Phase 1) 

Phase 1 Study of Continuous OSI-906 Dosing  (NCT00514007)

Phase 1 Study of Intermittent OSI-906 Dosing  (NCT00514306)

back to top